Otsuka agreed to acquire Transcend Therapeutics through its U.S. subsidiary in a deal worth about $1.2 billion, including a $700 million upfront payment and up to $525 million in milestones. The transaction targets Transcend’s TSND-201, an MDMA-analog designed to enhance “neuroplasticity” for PTSD and other psychiatric conditions. Transcend’s TSND-201 showed mid-stage results published in JAMA Psychiatry, and U.S. Phase 3 recruitment is now underway. Otsuka framed TSND-201 as a potentially paradigm-shifting therapy, emphasizing that the molecule is designed to avoid a key serotonin receptor linked to hallucinogenic effects. The acquisition further entrenches Otsuka’s neuropsychiatric pipeline strategy and brings a late-stage bet into a market shaped by the regulatory and clinical scrutiny that has already affected prior psychedelic-adjacent efforts.